Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-26-081559
Filing Date
2026-07-08
Accepted
2026-07-08 07:00:53
Documents
3
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 8175
2 EXHIBIT A tm2619944d1_ex99-a.htm EX-99.A 3953
3 EXHIBIT B tm2619944d1_ex99-b.htm EX-99.B 9743
  Complete submission text file 0001104659-26-081559.txt   23499
Mailing Address 12 HAMMERSMITH GROVE OFFICE 205 LONDON United Kingdom W6 7AP
Business Address 12 HAMMERSMITH GROVE OFFICE 205 LONDON United Kingdom W6 7AP 44-0-20-3457 6900
Silence Therapeutics plc (Subject) CIK: 0001479615 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92205 | Film No.: 261160748
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O SILENCE THERAPEUTICS INC. 72 HAMMERSMITH ROAD LONDON United Kingdom W14 8TH
Business Address
Griffiths Richard Ian (Filed by) CIK: 0001846370 (see all company filings)

Type: SCHEDULE 13D/A